Commitment contracts as a way to healthBMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e522 (Published 30 January 2012) Cite this as: BMJ 2012;344:e522
- Scott D Halpern, assistant professor of medicine 1234,
- David A Asch, professor of medicine12356,
- Kevin G Volpp, professor of medicine1256
- 1Leonard Davis Institute of Health Economics, Center for Health Incentives and Behavioral Economics, University of Pennsylvania
- 2Department of Medicine, University of Pennsylvania, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA
- 3Center for Bioethics, University of Pennsylvania
- 4Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
- 5VA Center for Health Equity Research and Promotion, University of Pennsylvania
- 6Department of Health Care Management, Wharton School, University of Pennsylvania
- Correspondence to: S D Halpern
- Accepted 5 December 2011
Much illness stems from poor health behaviours. But changing behaviours is difficult, particularly when immediate desires must be sacrificed to achieve future benefits,1 as when people try to quit smoking, eat less, or exercise more. To overcome these challenges, corporate ventures such as www.stickk.com and www.healthywage.com are banking, quite literally, on commitment contracts, offering the millions of people who struggle to lose weight or take their medicines more regularly the opportunity to deposit money that they will receive back only if they succeed. Grounded in behavioural economic theory,2 commitment contracts bring a risk of loss into the present, where the temptations also lie, and augment motivation to succeed. They potentially offer an efficient mechanism of behaviour change because people generally are more motivated to avoid losses than they are to achieve similarly sized gains.3
Although new to health promotion, the idea of making voluntary commitments that restrict future options has a rich history. Cortes scuttled his ships to enhance his soldiers’ commitments to overthrowing the Aztec empire. Odysseus lashed himself to his ship’s mast so he could hear the song of the Sirens but not be tempted to throw himself overboard. And for more than a century, people have saved money in Christmas club accounts that provide little or no interest and charge fees to prevent early withdrawals, despite the widespread availability of penalty-free savings accounts with higher interest rates. Indeed, recent evidence shows that some people use commitment contracts to help them save money,4 complete homework assignments on time,5 and limit their consumption of what they see as vices.6
Imposing restrictions on ourselves to overcome expected future temptations may seem irrational. But succumbing to the temptations all around us to engage in unhealthy behaviours is at least as irrational. Commitment contracts aim to redirect the irrationality that typically makes us fail to create situations where we are more likely to succeed. How well commitment contracts can achieve this aim, however, depends on five important criteria: efficacy, acceptability, effectiveness, cost effectiveness, and targeting.
The first question is how effective are commitment contracts at promoting healthier behaviours in participants? More specifically, what proportion of people who establish contracts actually achieve their goals, and how does the efficacy of contracts compare with that of other methods for promoting the same behaviours? Answers to these questions are just beginning to emerge, particularly in the context of weight loss.7 8 For example, a recent randomised controlled trial showed that roughly half of obese people participating in a 16 week commitment contract programme achieved their weight loss goal of 0.45 kg (1lb) a week, whereas only 10% of people receiving usual care did so.8 Similar findings emerged in a follow-up randomised trial of 32 week commitment contracts.9 However, in both of these trials, the early improvements in weight loss waned after the contracts ended, such that the benefits were no longer evident months later.8 9
In one sense, we should not be surprised. We do not expect drugs or other treatments to remain effective after they are no longer in use, and we should not hold commitment contracts to a higher standard. Instead, we should pursue future experiments designed to evaluate ways to promote the long term efficacy of commitment contracts, compare commitment contracts with non-incentive based interventions, determine what deposit amounts, frequency, timing, and duration are required to promote success (as in trials of new drugs), and assess whether recovery of deposits should be predicated on behaviours (such as participation in smoking cessation programmes) or on health outcomes (such as quitting smoking).
Another influential factor is likely to be what happens to deposited money in the event of failure; we might expect greater success if lost deposits were to go to causes or people one dislikes rather than a favourite charity. Or, as we are testing in a randomised trial of incentive programmes for smoking cessation, we might expect particularly high success rates if people’s forfeited money gets redistributed to competitors who succeed.10 Finally, for behaviours like reduced energy consumption that need to be sustained over time, provision of incremental matching funds or other extra incentives may be needed to keep people engaged.
A second factor for success is the acceptability of commitment contracts among people with unhealthy behaviours. What proportion will sign up for such contracts, and how can acceptability be augmented? One study has confirmed an intuition that the more people are asked to deposit, the less likely they are to participate.7 But we know little about how acceptance rates may vary in other settings. For example, in January 2012 www.stickk.com advertised that more than 130 000 contracts had been created through its website committing people to a broad range of behaviours. But these numbers say nothing about how many more people considered and rejected such contracts, or what characteristics of contracts make them acceptable.
As well as being affected by factors that also influence efficacy, acceptability may be affected by whether patients can choose the amount to be deposited, whether contracts are offered during times when we tend to be future oriented (for example, at New Year or after learning of a new diagnosis), and by whether or in what amounts matching funds are offered. For example, we are comparing the proportions of obese people receiving healthcare coverage through a large American insurer who will sign up for commitment contracts to lose weight that provide no match of deposited funds, a 1:1 match, or a 2:1 match. The hypothesis is that the greater the degree to which employers or insurers match the amounts deposited by individuals, the greater will be the initial uptake and the effectiveness of any given deposit.
Population effectiveness represents the product of uptake and efficacy (individual effectiveness conditional on uptake). To be effective (and efficient), contracts must be designed so that they do not simply attract highly motivated people who might change their behaviour on their own anyway; nor should they attract those who are unlikely to change their behaviour with them. The absolute and comparative effectiveness of commitment contracts are likely to influence employers’, insurers’, policy makers’, or others’ decisions to offer contracts. However, examining the individual components of acceptance and efficacy can help to build better programmes.
Consider two hypothetical commitment contracts for smoking cessation, both of which have expected values to participants of $400 (£260; €310) (table⇓). Programme A, a $200 deposit matched 1:1 by an employer, is accepted by 20% of people to whom it is offered, and 50% of those who accept it stop smoking. Programme B is a $50 deposit matched 7:1 by an employer. Because the deposit required by employees is much lower and the matching is much greater, we might expect this programme to have much greater acceptance (say 70%), but perhaps lesser efficacy (say 40%) because the larger deposits in programme A provide stronger motivation among those who accept. Although programme A has a higher efficacy (50% v 40%), programme B recruited more people and was therefore more effective in terms of numbers quitting (280 v 100 for programme A).
The fourth consideration is the cost effectiveness of commitment contracts. How does this compare with that of other approaches to behaviour change? And how sensitive are such estimates to the matching funds that may be needed to promote adequate acceptance and ongoing engagement? The commitment contracts offered presently through private firms that are surviving in the marketplace appear to be at least self supporting because they do not offer matching funds. Clearly, such programmes can be useful to individuals even if they have very low participation rates. But if insurers or employers wish to offer contracts to help sizeable proportions of their populations, their incremental cost effectiveness in changing behaviour is going to be central. Matching funds may be needed to increase acceptance rates and help sustain longer term behaviour change. As the table⇑ shows, the ratio of matching can be an important determinant of absolute and incremental cost effectiveness. However, because disbursements are contingent on success, even relatively high matching funds may be more cost effective than interventions (such as drugs) that are financed for all who use them regardless of outcomes.
Finally, we need to know for whom commitment contracts are most likely to be acceptable, efficacious, effective, and cost effective. In other words, what characteristics of people make them particularly likely to take up a contract and use it to achieve behaviour change, and how might consumer detailing be used to augment contracts’ effectiveness and cost effectiveness? We might expect that people most willing to accept commitment contracts are those who recognise their difficulties with resisting temptations and who are motivated to change this. People for whom commitment contracts have the greatest incremental efficacy may be those with particularly high levels of impulsivity.2 However, getting such people to accept the contracts may be a particular challenge. If we can identify people in whom commitment contracts are more effective, programmes could be targeted at these groups. Such data might also suggest ways to broaden the acceptability and efficacy of commitment contracts, perhaps through interventions that help people link present behaviours to future consequences.11
In summary, there is great conceptual strength to the idea that commitment contracts can provide a way to health for the millions of people struggling to modify health behaviours that they themselves recognise as harmful. However, before they are implemented we need a careful assessment of key design features. This is a nascent science in need of further experimentation. Only through careful investigation will we be able to determine whether commitment contracts measure up to their considerable promise.
Cite this as: BMJ 2012;344:e522
Contributors and sources: SDH and KGV each serve as principal investigator on randomised trials of commitment contracts for health improvements. All authors have reported widely on ethical and scientific issues arising with the use of behavioural economic interventions to improve health. This article arose from discussions in preparation for a grant from the National Cancer Institute (R01 CA159932) to SDH. All authors contributed equally to discussions about the content of this article before it was written. SDH wrote the first draft, and DAA and KGV made subsequent modifications on key intellectual elements.
Competing interests: All authors have completed the ICJME unified disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no financial support for the submitted work. All authors are supported by the National Institute on Aging and National Cancer Institute. KGV has received funding for investigator initiated research on financial incentives for medication adherence from Pfizer and the Aetna Foundation and has served as a consultant on financial incentives for McKinsey, Ascension Health, Vitalspring, and CVS Caremark. SDH, DAA, and KGV all believe in the importance of experiments to understand whether and how financial incentives (including commitment contracts) influence health related behaviours.
Provenance and peer review: Not commissioned; externally peer reviewed.